With shares of Corning (NYSE:GLW) trading around $17, is GLW an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.
T = Trends for a Stock’s MovementCorning produces and sells specialty glasses, ceramics, and related materials worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. Corning has launched Corning Lotus Glass, an environmentally friendly display glass for organic LED and LCD displays that are used in portable devices such as smartphones, tablets, and notebook computers. Smart phones, tablets, notebook computers, and their related materials are seeing explosive growth in developed and developing countries around the world.
Samsung Electronics���(SSNLF.PK)�purchase of Corning shares and a glass supply agreement between the two companies will last until 2023. Samsung Display is buying $2.3 billion worth of shares in Corning, according to a statement from Corning, making Samsung�� combined stake in Corning 7.4 percent. The Samsung purchase is expected to close in the first quarter of 2014.
Top 5 Machinery Companies To Own For 2015: Genetic Technologies Ltd (GENE)
Genetic Technologies Limited provides genetic testing services. It offers a range of DNA based genetic tests for cancer predisposition, including breast cancer, ovarian cancer, bowel cancer, and uterine cancer; neurogenetic diagnostic assays; and gene testing for gene related disorders. The company also provides forensics tests, such as presumptive and confirmatory testing, individual DNA profiling, species identification, and animal forensic testing; paternity tests, which include antenatal, deceased estate, grandparent, immigration, legal paternity, non-legal paternity, sibling, twins, and Y-Chromosome DNA testing, as well as DNA profiling; and personal DNA testing comprising sports performance and ancestry gene testing. In addition, it offers animals� tests consisting of disease testing, breed identification, coat color, and forensic DNA testing, as well as DNA clinical services; and plant tests, including genomic and Xpress sequencing services. Further, the company is involved in the out-licensing of its intellectual property relating to non-coding DNA; and research and development activities in the areas of genetics and related fields. It operates in Australia, the United States, China, Canada, and Switzerland. The company was formerly known as Duketon Goldfields N.L. and changed it name to Genetic Technologies Limited in August 2000 as a result of the change in business from mining to biotechnology. Genetic Technologies Limited is headquartered in Fitzroy, Australia
Advisors' Opinion:- [By Holly LaFon]
Eugene (Gene) Abegg is arguably the greatest banker nobody has ever heard of. In fact, Abegg could have been cast as a crusty version of George Bailey of the Bailey Building and Loan Association in Frank Capra's It's a Wonderful Life.
- [By John Udovich]
The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer with the overall costs of the disease topping $126 billion annually ��meaning there is a big market for small cap cancer diagnostic stocks like Rosetta Genomics Ltd. (NASDAQ: ROSG), Genetic Technologies Limited (NASDAQ: GENE) and MetaStat Inc (OTCBB: MTST) just in the US alone without considering global cancer figures. After all, catching and doing something about cancer early on is critical to increase survival rates and bring down the cost of treatment. With that in mind, here are three small cap cancer diagnostic stocks helping to lead the fight to diagnose and stop cancer:
- [By James E. Brumley]
Most likely it went unnoticed, but that doesn't mean it's not a big deal. What's that? Genetic Technologies Limited (NASDAQ:GENE) shares quietly slipped above their 100-day moving average line just a few moments ago, putting the finishing touches on a rebound effort that's been underway since October. With today's final piece of the puzzle being laid, the odds of a big bullish move from GENE here just skyrocketed.
Top 10 Life Sciences Companies To Invest In 2014: Emerson Electric Company(EMR)
Emerson Electric Co. operates as a diversified manufacturing and technology company. The company engages in appliance solutions, climate technologies, industrial automation, motor technology, network power, process management, professional tools, and storage solutions businesses. Its appliance solutions business provides appliance controls, appliance motors, heating products, and white-rodgers; climate technology business provides heating, ventilation, air conditioning, and refrigeration (HVACR) solutions for residential, industrial, and commercial applications; and industrial automation business offers bearings and power transmission products, electrical power generation products, electric motors, variable speed drives and servos, electrical products, material joining solutions, fluid automation products, and wind turbine systems. The company?s motor technology business provides appliance motors, HVACR motors, DC motors, fractional horsepower motors, integral horsepower a nd larger motors, and drives; network power business provides power, precision cooling, connectivity, and embedded solutions; and process management business provides various wireless related products from self-organizing field networks to wireless asset and people tracking. Its professional tools business offers pipe working and threading equipment, pressing technology, utility locating and visual diagnostics systems, drain maintenance tools, power tools, air tools, general purpose hand tools, wet/dry vacs, job site storage equipment, truck tool boxes and equipment, and van storage equipment; and storage solutions business provides shelving and storage products for residential, commercial, and foodservice needs, as well as offers specialized carts, mobile computer workstations, and cabinet fixtures. The company was founded in 1890 and is headquartered in St. Louis, Missouri.
Advisors' Opinion:- [By Chuck Saletta]
Emerson Electric (NYSE: EMR ) is a selection for the real-money Inflation-Protected Income Growth portfolio. Like any investment, it needs to be reviewed from time to time to see if it's still worth owning. In the brief video below, portfolio manager Chuck Saletta reviews its valuation, balance sheet, and dividends, and decides whether to hold on to the stock, or let it go.
- [By Chuck Carnevale]
Actually, there are several companies on these lists that qualified for either or both of my favorites lists. For example, Aflac (AFL) and or Emerson Electric (EMR) could easily be on both lists. My point is that I feel the reader should give the same consideration to each of these names as they would the two top 10 lists. To be clear, selecting the top 10 was difficult and therefore to a great extent subjective on my part. My method was to simply run a F.A.S.T. Graphs��on each Dividend Champion with above-average total return calculations. Then my lists were created by picking and choosing those companies that from my review looked best based on value, earnings and safety.
- [By Lee Jackson]
Rackspace Hosting Inc. (NYSE: RAX) recently added a huge new customer in Emerson Electric (NYSE: EMR). In January Emerson started using Rackspace to help tune and monitor climate control products for residential and commercial customers. Adoption has gone so well that Rackspace expects Emerson to hike its commitment from 43 servers today to 100 by year’s end. The consensus price target for the stock is posted at $52. The stock closed at $50.60.
Top 10 Life Sciences Companies To Invest In 2014: ATP Oil And Gas Corp (AOB)
ATP Oil & Gas Corporation, incorporated in 1991, is engaged in the acquisition, development and production of oil and natural gas properties. As of December 31, 2011, the Company had estimated net proved reserves of 118.9 Million barrels of crude oil equivalent (MMBoe), of which approximately 75.9 MMboe (64%) were in the Gulf of Mexico and 42.9 MMBoe (36%) were in the North Sea. The reserves consisted of 78.6 Million barrels (MMBbls) of oil (66%) and 241.5 billion cubic feet (Bcf) of natural gas (34%). Its proved reserves in the deepwater area of the Gulf of Mexico account for 62% of the Company�� total proved reserves and its proved reserves on the Gulf of Mexico Outer Continental Shelf account for 2% of its total proved reserves. During the year ended December 31, 2011, the Company acquired three licenses in the Mediterranean Sea covering potential natural gas resources in the deepwater off the coast of Israel (East Mediterranean). On August 17, 2012, ATP Oil And Gas Corp filed for Chapter 11 bankruptcy protection.
The Company�� natural gas reserves are split between the Gulf of Mexico (57%) and the North Sea (43%). Of its total proved reserves, 8.3 MMBoe (7%) were producing, 19.0 MMBoe (16%) were developed and not producing and 91.6 MMBoe (77%) were undeveloped. The Company�� average working interest in its properties at December 31, 2011, was approximately 81%. The Company operates 92% of its platforms. At December 31, 2011, in the Gulf of Mexico, it owned leasehold and other interests in 38 offshore blocks and 49 wells, including 23 subsea wells. The Company operates 43 (88%) of these wells, including 100% of the subsea wells. In the North Sea, it also had interests in 13 blocks and two Company-operated subsea wells. As of March 15, 2011, the Company owned an interest in 13 platforms, including two floating production facilities in the Gulf of Mexico, the ATP Titan at its Telemark Hub and the ATP Innovator at its Gomez Hub. It operates the ATP Innovator and the ATP Titan.
Advisors' Opinion:- [By John Emerson]
Most of the Chinese companies that I purchased now reside on the Pink Sheets or have disappeared altogether, but at one time they all traded on major US exchanges. One of them (AOB), even received the honor of ringing the opening bell at the New York Stock Exchange in 2007, and people say that crime does not pay.
Top 10 Life Sciences Companies To Invest In 2014: Agrium Inc.(AGU)
Agrium Inc., together with its subsidiaries, produces and markets agricultural nutrients, industrial products, and specialty products worldwide, as well as involves in the retail supply of agricultural products and services in North and South Americas. The company?s Retail segment markets crop nutrient products, including nitrogen, phosphate, potash, sulphur, and micronutrients; crop protection products, such as herbicides, fungicides, adjuvants, and insecticides; and seeds. This segment also offers agronomic services, as well as product application, soil and leaf tissue testing and analysis, and crop scouting services. This segment operates 1,192 outlets in the United States, Canada, Australia, Argentina, Chile, and Uruguay. The company?s Wholesale segment produces, markets, and distributes nitrogen, phosphate, potash, sulphate, and other crop nutrient products for agricultural and industrial customers. This segment also owns and operates facilities that upgrade ammonia t o other nitrogen products, such as urea, nitric acid, and ammonium nitrate, as well as provides Rainbow plant food products. Agrium?s Advanced Technologies segment produces and markets controlled-release crop nutrients and micronutrients for the agriculture, specialty agriculture, professional turf, horticulture, and consumer lawn and garden markets. The company was formerly known as Cominco Fertilizers Ltd. and changed its name to Agrium Inc. in 1995. Agrium Inc. was founded in 1931 and is headquartered in Calgary, Canada.
Advisors' Opinion:- [By Dan Burrows]
Whether it’s phosphates, sulfur or nitrogen, agriculture stocks have stunk up the market this year. Agrium (AGU), which sells all three through both wholesale and retail, has seen its stock fall 15% for the year-to-date, lagging the S&P 500 by 33 percentage points.
Top 10 Life Sciences Companies To Invest In 2014: PDL BioPharma Inc.(PDLI)
PDL BioPharma, Inc. engages in intellectual property asset management and royalty bearing assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Advisors' Opinion:- [By Brian Orelli]
PDL BioPharma (NASDAQ: PDLI ) did much better with the spin out of its development stage program into Facet Biotech. The biotech started trading at $13�per share, and was eventually taken out by Abbott for $27. The main assets now reside in Abbott's aforementioned spinout AbbVie in conjunction with Biogen Idec, which was developing the drugs with PDL. If the drugs are successful, maybe the duo will spin them out into a joint venture, completing the cycle?
Top 10 Life Sciences Companies To Invest In 2014: Cablevision Systems Corporation (CVC)
Cablevision Systems Corporation provides telecommunications and media services. It operates in two segments, Telecommunications Services and Other. The Telecommunications Services segment is involved in television business, including video, high-speed data, and VoIP operations, as well as the provision of commercial data and voice services. The Other segment offers Newsday, a daily newspaper; amNewYork, a free daily newspaper; and Star Community Publishing, a group of weekly shopper publications; and newsday.com and exploreLI.com. This segment also engages in motion picture theatre business, Clearview Cinemas; provision of the News 12 Networks, a regional news programming services; and the MSG Varsity network, a network covering high school sports and activities, and other local programs, as well as cable television advertising. Cablevision Systems Corporation was founded in 1985 and is headquartered in Bethpage, New York.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
'Interconnection' The better access that Netflix is getting from Comcast is known as "interconnection," a term referring to digital content's journey to an Internet service provider's gates. That path technically isn't covered by the current definition of Net neutrality, which refers to how service providers treat digital content once it's inside the gates. Comcast has promised to honor the previous rules governing Net neutrality through 2018. In a blog post last month, Hastings argued that future Net neutrality guidelines should be expanded to address interconnection issues, too. "Without strong Net neutrality, big ISPs can demand potentially escalating fees for the interconnection required to deliver high quality service," Hastings wrote. "The big ISPs can make these demands -- driving up costs and prices for everyone else -- because of their market position." Google's YouTube video site and many other websites were paying interconnection fees to Comcast before Netflix struck its own deal with the carrier. Even with the March improvements, Comcast's delivery of Netflix content lags behind several other major service providers. Cablevision (CVC), Cox, Suddenlink and Charter (CHTR) each delivered Netflix video at higher speeds than Comcast in March, according to Monday's breakdown. Netflix has interconnection deals with Cablevision, Cox and Suddenlink, although those arrangements don't require Netflix to pay fees.
- [By Tom Reese]
Regional cable TV and Internet provider Cablevision Systems Corporation (CVC) on Friday announced better-than-expected third quarter earnings results, reversing a year-ago loss.
Cablevision’s Q3 Earnings in Brief
- Net income totaled $294.6 million, or $1.10 per share, reversing last year’s loss of $3.79 million, or -1 penny per share.
- Revenue rose 1.8% from last year to $1.57 billion.
- Analysts expected much lower earnings of just 11 cents per share, on matching revenue.Latest Dividend Reiterated; Yield Surpasses Peers
In its earnings release, Cablevision announced it would continue its dividend payout of 15 cents per share. The latest dividend will be paid on Dec. 13 with an ex-dividend date of Nov. 20. The company has not raised its dividend payout since May of 2011.Despite the lack of dividend raise, CVC’s dividend yield of 3.84% compares favorably with other stocks in its industry. Time Warner Cable (TWC) offers a yield of 2.2%, while Comcast Corporation (CMCSA) yields just 1.65%. The average dividend yield for S&P 500 companies is around 2.5%, so Cablevision’s yield is well above both its industry average as well as the wider market average. Still, its lofty yield has come more as a result of poor price performance, rather than dividend increases.
Shares Rise, but Still Tail Indexes
Cablevision shares rose more than 2% in early trading on Friday, but the company’s stock performance has lagged the wider markets for quite some time. Year-to-date, CVC has gained about 6%, compared with a 24% gain in the benchmark S&P 500 index. The stock was trading around the $38 level as recently as early 2011, so its dividend yield has risen significantly as its stock price plunged to around $16. - [By Paul Ausick]
SNL Kagan noted that cable outfits like Comcast Corp. (NASDAQ: CMCSA), Time Warner Cable (NYSE: TWC) and Cablevision Corp. (NYSE: CVC) saw subscriber losses double to 607,000. Cable�� share of the pay TV market has now fallen to 55.3%.
- [By Will Ashworth]
Losing control of the Cablevision (CVC) spinoff will ultimately be better for the Dolans than if they try to go it alone.
This scenario�� likely a long shot, but I think it makes a lot of sense.
Top 10 Life Sciences Companies To Invest In 2014: IDEXX Laboratories Inc (IDXX)
IDEXX Laboratories, Inc., incorporated in 1983, develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company operates through three segments: diagnostic and information technology-based products and services for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller segments that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.
The Company sells a range of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its primary products and services are point-of-care veterinary diagnostic products, consisting of instruments and consumables and rapid assays; veterinary reference laboratory diagnostic and consulting services used by veterinarians; diagnostic and health-monitoring products for livestock and poultry; products that test water for certain microbiological contaminants; practice management systems and services and digital radiography systems used by veterinarians; products that test milk for antibiotic residues and other contaminants, and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market.
Companion Animal Group
The Company markets a range of in-clinic laboratory analyzers for use in providing reference laboratory quality diagnostic results in companion animal veterinary practices, which it refers ! to as the IDEXX VetLab suite of analyzers. The Company sells two chemistry analyzers, the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, that are used by veterinarians to measure levels of certain enzymes and other substances in blood or urine for monitoring health status and assistance in diagnosing physiologic conditions. Both instruments use consumables manufactured for IDEXX by Ortho-Clinical Diagnostics, Inc. (Ortho), a subsidiary of Johnson & Johnson, based on Ortho�� dry slide technology (Catalyst Dx slides, VetTest slides or slides). In addition, the Catalyst Dx analyzer also uses dry slide electrolyte consumables manufactured by IDEXX at OPTI Medical Systems, one of its wholly owned subsidiaries. Blood tests commonly run on these analyzers include glucose, alkaline phosphatase, alanine aminotransferase (ALT), albumin, creatinine, blood urea nitrogen (BUN), and total protein. Tests are sold individually and in prepackaged panels. Both analyzers also run a urine test called urine protein:creatinine ratio, which assists in the detection of early renal disease.
The Catalyst Dx analyzer is the Company�� chemistry analyzer. The Catalyst Dx analyzer allows a veterinarian to run multiple patient samples simultaneously; to run different sample types, including whole blood, plasma, serum and urine; to perform 28 different chemistry and electrolyte tests; and to automatically calculate other parameters and ratios important to blood chemistry analysis. Its VetLyte Electrolyte Analyzer measures three electrolytes-sodium, potassium and chloride-to aid in evaluating acid-base and electrolyte balances and assessing plasma hydration. Its VetStat Electrolyte and Blood Gas Analyzer measures electrolytes, blood gases, glucose and ionized calcium, and calculates other parameters, such as base excess and anion gap. These measurements aid veterinarians in diagnosing various disease states, evaluating fluid therapy choices and measuring respiratory function. The VetStat analyzer ru! ns single! -use disposable cassettes that contain various configurations of analytes. The VetStat analyzer and its cassettes are manufactured by OPTI Medical Systems.
The Company sells three hematology analyzers that assess the cellular components of blood, including red blood cells, white blood cells and platelets (also called a complete blood count (CBC)). These analyzers include the ProCyte Dx Hematology Analyzer, which uses laser-flow cytometry, optical fluorescence and laminar-flow impedance in its analysis; the LaserCyte Hematology Analyzer, which uses laser-flow cytometry technology in its analysis, and the IDEXX VetAutoread Hematology Analyzer. It also sells the Coag Dx Analyzer, which permits the detection and diagnosis of blood clotting disorders. The ProCyte Dx analyzer provides validated results for five species (canine, feline, equine, bovine and ferret) for up to 24 different blood parameters, providing a more complete picture of each patient�� health.
The SNAPshot Dx analyzer provides quantitative measurements of total thyroxine (T4), cortisol and bile acids to assist in the evaluation of thyroid, adrenal and liver function. The SNAPshot Dx analyzer also reads, interprets and records the results of many IDEXX rapid assay SNAP tests, including its canine SNAP 4Dx test, feline SNAP FIV/FeLV Combo test, canine SNAP cPL test, feline SNAP fPL test, SNAP Feline Triple test and canine SNAP Heartworm RT test. The IDEXX VetLab UA Analyzer provides chemical urinalysis and is validated specifically for veterinary use. The IDEXX VetLab Station (IVLS) connects and integrates the diagnostic information from all the IDEXX VetLab equipment and thus provides reference laboratory information management system capability. It sells the IVLS as an integral component of the Catalyst Dx, LaserCyte and ProCyte Dx analyzers and also as a standalone hardware platform.
The IVLS includes a user interface to input patient information, connect with a practice management system and send i! nformatio! n to run the individual analyzers. IVLS also generates one integrated patient report incorporating all of the lab work generated by the IDEXX VetLab suite; stores, retrieves and analyzes historical patient diagnostics data, including SNAP test results; and sends and receives information from practice management systems, including the IDEXX Cornerstone system, as well as a variety of third-party systems. It sells a range of single-use, handheld test kits under the SNAP name. In addition to its single-use tests, it sells a range of microwell-based test kits under the PetChek name for canine heartworm, FIV and FeLV.
The Company offers commercial reference laboratory diagnostic and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, South Africa, China and South Korea and to bioresearch customers in the United States and Europe. The Company provides specialized veterinary consultation, telemedicine and advisory services, including radiology, cardiology, internal medicine and ultrasound consulting. It develops, markets and sells practice management systems, including hardware and software, and services that run certain functions of veterinary clinics, including managing patient electronic health records, scheduling (including boarding and grooming), reminders, billing and inventory management.
The Company markets and sells two digital radiography systems for use in the small animal veterinary hospital: the IDEXX-DR 1417 and the IDEXX I-Vision CR. Its digital radiography systems use IDEXX-PACS and IDEXX EquiView PACS picture archiving and communication system (PACS) software for the viewing, manipulation, management, storage and retrieval of the digital images generated by the digital capture plate. In September 2011, the Company launched IDEXX I-Vision Mobile, an application that allows veterinarians with the IDEXX-DR 1417 and IDEXX I-Vision CR systems, as well as its digital radiography systems, to request, view and send images using an iPa! d or an A! ndroid mobile tablet. This application integrates with its IDEXX-PACS software.
Water
The Company offers a range of products used in the detection and quantification of various microbiological parameters in water. Its principal products are the Colilert, Colilert-18 and Colisure tests, which simultaneously detect the presence of total coliforms and E. coli in water. These organisms are used as indicators of microbial contamination in water. These products utilize indicator-nutrients that produce a change in color or fluorescence when metabolized by target microbes in the sample. Its water tests are used by government laboratories, water utilities and private certified laboratories to test drinking water. The tests also are used in evaluating water used in production processes (for example, in beverage and pharmaceutical applications) and in evaluating bottled water, recreational water, waste water and water from private wells.
Livestock and Poultry Diagnostics
The Company sells diagnostic tests and related instrumentation that are used to detect a range of diseases and to monitor health status in livestock and poultry. Its livestock and poultry diagnostic products are purchased by government and private laboratories that provide testing services to cattle, swine and poultry veterinarians and producers. Its principal products include tests for Bovine Viral Diarrhea Virus (BVDV), Porcine Reproductive and Respiratory Syndrome (PRRS) and Bovine Spongiform Encephalopathy (BSE or mad cow disease). BVDV is a common and contagious viral infection that suppresses the immune system, making the animal susceptible to a host of other infections, impacting beef and dairy production yields as a result. PRRS is a contagious virus causing reproductive problems and respiratory diseases. BSE is a fatal neurodegenerative disease in cattle that causes a spongy degeneration in the brain and spinal cord.
Other
The principal products in the Company�! � Dairy ! business are its SNAP tests used to detect antibiotic drug-residue in milk. Its primary product line for detecting antibiotic residue in milk is SNAP Beta-Lactam, which detects penicillin, amoxicillin, ceftiofur and cephaphirin residues, followed by SNAPduo Beta-Tetra, which detects certain tetracycline antibiotic residues in addition to those detected by the SNAP Beta Lactam test kits. It also sells SNAP tests for the detection of certain other contaminants in milk, such as chemical melamine and Alfatoxin M1.
The Company sells OPTI point-of-care analyzers and related consumables for use in human medical hospitals and clinics to measure electrolytes, blood gases, acid-base balance, glucose, lactate, BUN and ionized calcium, and to calculate other parameters, such as base excess and anion gap. These analyzers are used primarily in emergency rooms, operating rooms, cardiac monitoring areas and other locations where time-critical diagnostic testing is performed within the hospital setting. The OPTI CCA and OPTI Touch Electrolyte and Blood Gas Analyzers run single-use disposable cassettes that contain various configurations of analytes; the OPTI R Analyzer runs reusable cassettes in various analyte configurations; and the OPTI LION Stat Electrolyte Analyzer runs single-use electrolyte cassettes. OPTI Medical Systems also manufactures its VetStat analyzer and provides the electrolyte module and dry slide reagents that make up the electrolyte testing functionality of the Catalyst Dx analyzer.
The Company competes with VCA Antech, Inc., Abaxis, Inc., Butler, Radiometer A/S, Siemens Medical Solutions Diagnostics, Instrumentation Laboratory, Abbott Diagnostics and Roche Diagnostics.
Advisors' Opinion:- [By Tim Brugger]
After 10 years on the board of IDEXX Laboratories (NASDAQ: IDXX ) , including serving on its audit and compensation committees, Brian McKeon has been named IDEXX's new executive vice president and CFO, the company announced today. McKeon's appointment as CFO becomes effective Jan. 1, though he has resigned from the IDEXX board as of Oct. 11, the company said.
- [By Sean Williams]
On the diagnostic side, there isn't a company better equipped to help veterinarians diagnose bone and organ disease, or help veterinarians improve the efficiency of their software, than IDEXX Laboratories (NASDAQ: IDXX ) . From small diagnostic analyzers to high-tech digital imagery and even consultation calls, IDEXX does it all for owners and veterinarians. The best part is that the company's companion diagnostics make up the bulk (83%) of its revenue, so the chance of IDEXX seeing a slowdown in demand appears pretty minimal.
- [By CanadianValue]
Idexx (IDXX) performed well in 2011, generating solid revenue growth and high-teens earnings growth thanks to a slight recovery in the veterinary end market, the ramp up of its new ProCyte hematology instrument, continued share gains in reference laboratories and one-time gains from production animal disease eradication programs in Europe. While we continue to like the company�� prospects and are impressed with its execution in a still sluggish market for animal healthcare, we trimmed our position in 2011 at prices we found attractive given our expectations for the business.
- [By Sean Williams]
Ignore this trend at your own risk
If you choose to do nothing, then you're playing right into the hands of pharmaceutical giants like Zoetis (NYSE: ZTS ) , Merck (NYSE: MRK ) , and IDEXX Laboratories (NASDAQ: IDXX ) , which are counting on your indifference to drive their profits.
No comments:
Post a Comment